Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 18 (Search time: 0.01 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2019Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemiaRoss, D.; Pagani, I.; Irani, Y.; Clarson, J.; Leclercq, T.; Dang, P.; McLean, J.; Saunders, V.; Carne, L.; Reynolds, J.; Ritchie, D.; White, D.; Branford, S.; Hughes, T.; Yong, A.
2006Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABLRoss, D.; Branford, S.; Moore, S.; Hughes, T.
2018Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cellsRoss, D.; Pagani, I.; Shanmuganathan, N.; Kok, C.; Seymour, J.; Mills, A.; Filshie, R.; Arthur, C.; Dang, P.; Saunders, V.; Braley, J.; Yong, A.; Yeung, D.; White, D.; Grigg, A.; Schwarer, A.; Branford, S.; Hughes, T.
2016BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemiaLatham, S.; Bartley, P.; Budgen, B.; Ross, D.; Hughes, E.; Branford, S.; White, D.; Hughes, T.; Morley, A.
2010Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Bartley, P.; Slader, C.; Field, C.; Dang, P.; Filshie, R.; Mills, A.; Grigg, A.; Vaz de Melo, J.; Hughes, T.
2013Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CMLBranford, S.; Yeung, D.; Ross, D.; Prime, J.; Field, C.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Sullivan, B.; Briggs, N.; Hertzberg, M.; Seymour, J.; Reynolds, J.; Hughes, T.
2013Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER studyRoss, D.; Branford, S.; Seymour, J.; Schwarer, A.; Arthur, C.; Yeung, D.; Dang, P.; Goyne, J.; Slader, C.; Filshie, R.; Mills, A.; Vaz de Melo, J.; White, D.; Grigg, A.; Hughes, T.
2014Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBranford, S.; Yeung, D.; Parker, W.; Roberts, N.; Purins, L.; Braley, J.; Altamura, H.; Yeoman, A.; Georgievski, J.; Jamison, B.; Phillis, S.; Donaldson, Z.; Leong, M.; Fletcher, L.; Seymour, J.; Grigg, A.; Ross, D.; Hughes, T.
2019Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remissionShanmuganathan, N.; Braley, J.; Yong, A.; Hiwase, D.; Yeung, D.; Ross, D.; Hughes, T.; Branford, S.
2014The adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatmentBranford, S.; Yeung, D.; Ross, D.; Parker, W.; Braley, J.; Seymour, J.; Hughes, T.; 56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)